Fisher Scientific and Nanogen expanded their relationship to include an R&D collaboration in molecular diagnostics. This agreement follows Fisher’s recent investment in Nanogen.
Under the agreement, Fisher could provide up to $10 million in total during 2007 and 2008 for the R&D of infectious disease and mutually agreed upon molecular diagnostic tests and the two companies will share technology and patent rights for the development and marketing of the new tests.
In addition, Nanogen and Athena Diagnostics, a subsidiary of Fisher Scientific, agreed to develop, manufacture, and market products based on Athena’s biomarkers for research and for in vitro diagnostics. Nanogen would have access to Athena’s biomarkers to develop new tests based, on its microarray platform the NanoChip400.